Accumulating evidence indicates that the regimen to increase adiponectin will provide a novel therapeutic strategy for inflammation and cardiovascular disorders. Here, we tested the effect of troglitazone (TG) and its newly synthesized derivative, 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thiazo lidinedione (Delta2troglitazone, (Delta2TG)), on the adiponectin expression in monocytes/macrophages and the relative mechanisms. The expression of adiponectin was located in macrophages of atherosclerotic lesions from patients and cholesterol-fed rabbits. TG and Delta2TG enhanced adiponectin mRNA and protein expression in THP-1 cells by quantitative real-time PCR, Western blot, and immunocytochemistry. TG induced adiponectin mRNA expression through a PPARgamma-dependent pathway whereas Delta2TG enhanced adiponectin mRNA expression through a PPARgamma-independent pathway in THP-1 cells. Both TG and Delta2TG enhanced adiponectin mRNA expression through AMP-activated protein kinase (AMPK) activation. TG and Delta2TG decreased the adhesion of THP-1 cells to TNF-alpha-treated HUVECs and the inhibitory effect was abolished by specific antiadiponectin antibodies. TG- and Delta2TG-induced suppression on monocyte adhesion were inhibited by a selective AMPK inhibitor compound C. Our data suggest that the inhibitory effect of TG and Delta2TG on monocyte adhesion might be at least in part through de novo adiponectin expression and activation of an AMPK-dependent pathway, which might play an important role in anti-inflammation and antiatherosclerosis.
Date:
2014-09-22
Relation:
Mediators of Inflammation. 2014 Sep 22;2014:Article number 726068.
